HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102

Inclusion Criteria: 1. Subject who was informed of, and fully understood, all aspects of the study and has provided voluntary written consent for participation in the study 2. Subject aged over 19 years at the time of consent provided 3. Subject with planned liver transplantation due to HBV-related end-stage liver disease such as cirrhosis, liver cancer and fulminant hepatic failure 4. Subject with HBsAg(+) Exclusion Criteria: 1. Subject with planned reoperation following liver transplantation 2. Subject with hemophilia 3. Subject with a history of venous or arterial thrombosis 4. Subject with HAV, HCV or HIV infection 5. Subject with immunodeficiency or immunosuppression due to whole body steroids before liver transplantation 6. Subject with hemolytic or blood loss anemia 7. Subject with IgA deficiency 8. Subject with a history of malignant tumor within the last 5 years, excluding primary liver cancer 9. Subject with moderate to severe kidney disease (serum creatinine \> 20mg/dL or anuria, kidney failure or dialysis) 10. Subject with a history of transient ischemic attack(TIA), myocardial infarction(MI), unstable angina, cerebral infarction, cerebral hemorrhage, percutaneous transluminal angioplasty(PTA) or coronary artery bypass graft(CABG) within the last 6 months prior to the screening 11. Subject with severe heart failure(NYHA class III\~IV), arrythmia requiring treatment 12. Subject with known hypersensitivity (anaphylaxis) to any component of the study drug 13. Subject who had received other immunoglobulin product within the last 3 months prior to the study entry 14. Subject who had received live parenteral vaccine (MMR, Cholera and Varicella) within the last 3 months prior to the study entry 15. Subject who had received estrogen or hormone alternative medicine 16. Pregnant or breast-feeding women 17. Woman of childbearing potential with positive pregnancy test confirmed by serum beta-human chorionic gonadotropin(B-HCG) test within 28 days prior to dosing by urine pregnancy or Subject who refused to use a reliable method of contraception 18. Alcohol or drug abuse within 6 months 19. Subject who has participated in any other clinical trial within 30 days 20. Subject who has any clinically meaningful disease investigator's judgement to prevent participating in this study